Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | XPO1 | O14980 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381363 | 0.92 | CNR2 (0.60) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3382951 | 0.86 | CNR2 (0.46) | CNR2CYP1A2XPO1 | |
| SCHEMBL3381078 | 0.84 | CNR2 (0.59) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3382111 | 0.84 | CNR2 (0.53) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3382356 | 0.82 | CNR2 (0.46) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3378616 | 0.81 | CNR2 (0.62) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5079751 | 0.81 | CNR2 (0.57) | CNR2CYP1A2CYP2C9 | |
| SCHEMBL27694711 | 0.81 | CNR2 (0.72) | CNR2JAK2CYP1A2CYP2C9XPO1 | |
| SCHEMBL3378732 | 0.81 | CNR2 (0.63) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3379533 | 0.80 | CNR2 (0.52) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100351239-C | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LTD (GB) | 2007-11-28 | — | — | CN | claimed |
| EP-1878725-B1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
| EP-1878725-A2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | CNR2, CNR1, P2RX3 | CNR2 1/4885JAK2 887/4885JAK1 2800/4885 |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | CNR2, CNR1, P2RY2 | CNR2 1/4885JAK2 976/4885JAK1 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.